Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Cell therapy | 1 |
Antibody drug conjugate (ADC) | 1 |
Dendritic cell vaccine | 1 |
Monoclonal antibody | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism RYR2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CALR modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date18 Mar 2024 |
Sponsor / Collaborator |
Start Date01 Jan 2024 |
Sponsor / Collaborator |
Start Date01 Dec 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Tax peptide-pulsed dendritic cell vaccine | T-Cell Lymphoma More | Phase 1 |
GCT-102 | Cerebral Palsy More | Preclinical |
TG-003 ( CLK x CLK4 ) | Neoplasms More | Preclinical |
Anti-CD64 antibody-drug conjugate(Tokyo Medical and Dental University/Kyowa Hakko Kirin) ( CD64 ) | Chronic Myelomonocytic Leukemia More | Preclinical |
TMDJ-035 ( RYR2 ) | Arrhythmias, Cardiac More | Preclinical |